DSIP (Delta Sleep-Inducing Peptide)

The Barrier Any Central Claim Has to Cross

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

The blood-brain barrier excludes most circulating peptides. Any claim that a peptide acts centrally requires it to cross, be transported, or act at a site outside the barrier, and which of those applies is rarely specified.

Key facts

Barrier formed by
Tight junctions between endothelial cells
Excludes
Most peptides and hydrophilic molecules
Routes across
Transporters, receptor-mediated transcytosis
Exception sites
Circumventricular organs
Review
Zhou 2021 (PMID 33470550)
DSIP charge
Strongly acidic, unfavourable

What the barrier is

Brain capillary endothelial cells are joined by tight junctions that prevent material passing between them, so anything entering must go through the cells rather than around them. That requires either lipid solubility sufficient to cross membranes or a specific transporter. Most peptides have neither.

Why charge makes it harder

Charged molecules do not partition into lipid membranes. DSIP is strongly acidic, carrying negative charge at physiological pH, which is among the least favourable profiles for passive entry. A neutral, small, lipophilic molecule crosses readily; a charged nine-residue peptide does not.

Research material referenced

DSIP 5mg, third-party HPLC tested

Buy DSIP · £13.95

The routes that do exist

Specific transporters carry particular molecules across, and receptor-mediated transcytosis moves larger cargo by binding a receptor and being ferried through the cell. Both are selective. A molecule benefits only if a transporter or receptor recognises it, which is why brain penetration is engineered rather than assumed. Zhou and colleagues reviewed the strategies in 2021.

The sites where the barrier is absent

Circumventricular organs, including the area postrema, sit outside the barrier so they can sample blood directly. A circulating peptide can act there without crossing anything, and this is how incretin agonists produce central effects on nausea. It is a real route, and it reaches only a small number of specific structures.

Why this is the unstated assumption in the DSIP story

The original experiment introduced the peptide into the ventricles, directly into cerebrospinal fluid, bypassing the barrier entirely. That is a legitimate experimental route and it establishes nothing about whether the peptide reaches the brain from circulation. Any account of peripheral administration producing a central effect owes an explanation of how, and the literature does not supply one.

Why this generalises

Several compounds in this catalogue carry central claims: Semax, Selank, DSIP. Each faces the same question, and in each case the answer is either a transport route, a circumventricular site, or an assumption. Identifying which is a fair test to apply to any claim about a peptide acting on the brain.

Frequently asked questions

Why can't most peptides enter the brain?

Tight junctions force entry through endothelial cells, requiring lipid solubility or a specific transporter. Most peptides have neither.

Does charge matter?

Considerably. Charged molecules do not partition into membranes, and DSIP is strongly acidic, which puts it among the least favourable profiles.

How did the original DSIP experiment get around this?

It introduced the peptide into the ventricles, bypassing the barrier entirely, which establishes nothing about entry from circulation.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More DSIP (Delta Sleep-Inducing Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.